₹1491.15▲0.44%
0.01%
Low
Day's Volatility:0.10%
High
0.09%
38.14%
Low
52 Weeks Volatility:48.04%
High
9.91%
Returns % | |
1 Month Return | -7.1 % |
3 Month Return | 7.42 % |
1 Year Return | 51.63 % |
Market Stats | |
Previous Close | ₹1,483.75 |
Open | ₹1,491.60 |
Volume | 91.60L |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹3,56,217.27Cr |
based on 35 analysts
Based on 35 analysts offering long term price targets for Sun Pharmaceuticals Industries Ltd. An average target of ₹1569.57
Source: S&P Global Market Intelligence
Organisation | Sun Pharmaceuticals Industries Ltd |
Headquarters | Mumbai |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Today's Timeline - 24 Apr
11:33 AM
-Motilal Oswal recommends 'Buy' rating on Sun Pharma with a target price of Rs 1,870. Expects 19% earnings CAGR over FY24-26 led by specialty/EM-ROW/DF segments.
11:50 AM
-Motilal Oswal sees 26% upside in Sun Pharma due to its interesting specialty pipeline for addressing patients needs in areas of dermatology, ophthalmology, and onco-dermatology.
Key events for Sun Pharmaceuticals Industries Ltd
Sun Pharma's specialty pipeline is expected to register 20% CAGR over FY24-26, leading to an overall R&D expenditure increase of 18% CAGR. Motilal Oswal values Sun Pharma at 30x 12M forward earnings.
Sun Pharma Monitoring Situation in Israel - 20 Apr, 2024
Sun Pharmaceuticals Industries Ltd is monitoring the situation in Israel through its subsidiary, Taro Pharmaceutical, and taking necessary steps to ensure employee safety.
Sun Pharma's Taro Pharmaceutical may face supply chain issues - 19 Apr, 2024
Sun Pharma's subsidiary, Taro Pharmaceutical, based in Israel, could experience supply chain problems. Companies like Sun Pharma Lupin, Torrent, and Divis Labs are likely to be affected due to their significant presence in the MENA region.
Sun Pharma Faces Regulatory Challenges - 18 Apr, 2024
Sun Pharmaceuticals Industries Ltd faces regulatory challenges after its Dadra facility was classified as Official Action Indicated (OAI) by the US FDA. Analysts and investors hold a bearish view on the stock, which may fall up to Rs 1,330 apiece in the rest of the month.
Delhi High Court Upholds Order Against Glenmark Pharmaceuticals - 17 Apr, 2024
The Delhi High Court has upheld its order restraining Glenmark Pharmaceuticals from manufacturing, selling or advertising its asthma drug under the mark Indamet or any other deceptively similar mark to Sun Pharma's Istamet XR CP until the case is disposed of.
Sun Pharma Shares Decline on Regulatory Concerns - 15 Apr, 2024
Sun Pharma's shares decline due to USFDA issuing an OAI tag to its Mumbai unit, which may impact new launches. Analysts expect limited earnings impact but see a regulatory overhang for the drugmaker.
Sun Pharma Shares Fall After US FDA Classification - 12 Apr, 2024
Sun Pharmaceutical Industries Ltd faced a significant setback when its Dadra facility was classified as Official Action Indicated by the US Food and Drug Administration, leading to a 4% decline in share prices. The company will cooperate with regulators to achieve compliance status.
Sun Pharma's Future Looks Bright Amid Positive Forecasts - 09 Apr, 2024
Indian pharma companies are expected to see significant YoY revenue growth in Q4 FY24. Prabhudas Lilladher maintains its bullish stance on healthcare sector and has picked Sun Pharma as its top pick with a BUY rating and target price of Rs 1,640.
Sun Pharma Drops for Fifth Straight Session - 08 Apr, 2024
Sun Pharmaceuticals Industries Ltd has dropped for a fifth straight session and is quoting at Rs 1602.95, down 0.38% on the day as of 13:19 IST on the NSE. The volume in the stock stood at 5.96 lakh shares today.
Sun Pharma Appoints New CIO - 04 Apr, 2024
Sun Pharmaceuticals Industries Ltd has appointed Dheeraj Sinha as the new Executive Vice President and Chief Information Officer, effective from April 3, 2024. He replaces Anil Rao who resigned for personal reasons.
Sun Pharma Receives High Buy Calls from Analysts - 03 Apr, 2024
Sun Pharmaceutical Industries receives high optimism from analysts due to its strong standing in the global specialty space and robust outlook for its India business. The company's MD, Dilip Shanghvi, is India's richest man. Additionally, Mr. Dheeraj Sinha replaces Mr. Anil Rao as EVP and CIO.
Sun Pharma Hits 52-Week High Amid Positive Outlook - 28 Mar, 2024
Sun Pharmaceuticals Industries Ltd's stock hit a new 52-week high amid a positive outlook for its specialty portfolio. HSBC maintained a buy rating and raised the target price to Rs 1790. The filing of Nidlegy with the EU regulator and FDA approval for alopecia drug 900 deuruxolitinib are key catalysts for future growth.
Sun Pharma Founder Dilip Shanghvi's Wealth Reaches ₹1,64,300 Crore - 27 Mar, 2024
Dilip Shanghvi, the founder of Sun Pharmaceutical Industries, has a wealth of ₹1,64,300 crore. The Mumbai-based company remains a powerhouse in the pharmaceutical industry and continues to grow under his leadership.
Fundamentals of Sun Pharmaceuticals Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Retail Holding Up
Retail Investor have increased holdings from 8.92% to 8.97% in Mar 2024 quarter
Best in 1 Year
In the last 1 year, SUNPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
Profit Spike
Netprofit is up for the last 4 quarters, 1.98K Cr → 2.52K Cr (in ₹), with an average increase of 7.5% per quarter
Revenue Rich
Revenue is up for the last 4 quarters, 11.30K Cr → 12.63K Cr (in ₹), with an average increase of 3.6% per quarter
FII Holding Up
Foreign Institutions have increased holdings from 17.07% to 17.72% in Mar 2024 quarter
Best in 3 Years
In the last 3 years, SUNPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
Promoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Mar 2024 quarter
Price Dip
In the last 1 month, SUNPHARMA stock has moved down by -7.1%
MF Holding Down
Mutual Funds have decreased holdings from 12.93% to 12.21% in Mar 2024 quarter
Sun Pharmaceuticals Industries Ltd in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (40.02x)
April 23, 2024
Industry (61.41x)
April 23, 2024
Highest (184.63x)
August 28, 2020
Funds | Holdings |
ICICI Prudential Value Discovery Fund Direct Plan Growth | 6.09% |
ICICI Prudential Bluechip Fund Direct Plan Growth | 2.69% |
ICICI Prudential Equity & Debt Fund Direct Plan Growth | 3.9% |
Axis Bluechip Fund Direct Plan Growth | 3.64% |
Nippon India Pharma Fund - Direct Plan - Growth Plan | 14.91% |
Investors | Holdings % | Prev. 1 periods | 3M change |
---|---|---|---|
Promoter Holdings | 54.48% | 0.00 | |
Foreign Institutions | 17.72% | 0.00 | |
Mutual Funds | 12.21% | 0.00 | |
Retail Investors | 8.97% | 0.00 | |
Others | 6.61% | 0.00 |
Technicals of Sun Pharmaceuticals Industries Ltd share
News & Events of Sun Pharmaceuticals Industries Ltd
News
Bajaj Finance Share Price: बजाज फाइनेंस के शेयर आज करीब 1 फीसदी मजबूत हुए हैं। इसके शेयरों में यह तेजी ब्रोकरेज फर्म Emkay Global के रुझान के चलते है जिसने खरीद... Read more
24 Apr, 2024 11:21 AMBajaj Finance projects strong Q4 results with expected profit and NII growth. Despite RBI restrictions affecting loans, AUM reached Rs 3.3 lakh crore. Key aspec... Read more
24 Apr, 2024 11:40 AMStock Market- ब्रोकरेज फर्म Emkay Global ने बजाज फाइनेंस शेयर पर कवरेज शुरू की है. ब्रोकरेज ने बजाज फाइनेंस शेयर में पैसा लगाने की सलाह निवेशकों को दी है.
24 Apr, 2024 12:47 PMSun Pharmaceuticals Industries Ltd (SUNPHARMA) share price today is ₹1491.15
Sun Pharmaceuticals Industries Ltd is listed on NSE
Sun Pharmaceuticals Industries Ltd is listed on BSE
PE Ratio of Sun Pharmaceuticals Industries Ltd is 40.02
PE ratio = Sun Pharmaceuticals Industries Ltd Market price per share / Sun Pharmaceuticals Industries Ltd Earnings per share
Today’s traded volume of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is 91.60L.
Today’s market capitalisation of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is ₹356217.27Cr.
Sun Pharmaceuticals Industries Ltd(SUNPHARMA | Price |
---|---|
52 Week High | ₹1638.85 |
52 Week Low | ₹922.45 |
Sun Pharmaceuticals Industries Ltd(SUNPHARMA) share price is ₹1491.15. It is down -9.01% from its 52 Week High price of ₹1638.85
Sun Pharmaceuticals Industries Ltd(SUNPHARMA) share price is ₹1491.15. It is up 61.65% from its 52 Week Low price of ₹922.45
Sun Pharmaceuticals Industries Ltd(SUNPHARMA | Returns |
---|---|
1 Day Returns | 6.5% |
1 Month Returns | -7.1% |
3 Month Returns | 7.42% |
1 Year Returns | 51.63% |